Benefits
Fibrinolytic Activity
Nattokinase directly cleaves fibrin (the protein scaffold of blood clots) — distinct from anticoagulants (which prevent clot formation by inhibiting clotting factors) and antiplatelets (which prevent platelet aggregation). Activates endogenous tissue plasminogen activator (tPA) and degrades fibrin directly.
Blood Pressure Modest Reduction
Kim 2008 and Jensen 2016 RCTs showed nattokinase (2,000 FU/day) modestly reduced both systolic and diastolic blood pressure in pre/hypertensive adults vs placebo. Effect size ~5-6 mmHg systolic — clinically meaningful but modest.
Cardiovascular Risk Markers
Several trials show nattokinase reduces fibrinogen, factor VII, and factor VIII levels — plus may reduce LDL and triglycerides, raise HDL. Multi-mechanism cardiovascular support.
Deep Vein Thrombosis (DVT) Prevention (Theoretical)
Cesarone 2003 trial showed nattokinase (2 capsules/day) reduced edema and DVT incidence vs placebo on long-haul flights. Mechanism plausible; sample size limited. Standard DVT prevention for high-risk patients remains anticoagulants and compression.
Long-COVID / Spike Protein Research (Emerging)
Recent in vitro research (Tanikawa 2022) suggests nattokinase may degrade SARS-CoV-2 spike protein. Generated significant interest in long-COVID and post-vaccine spike protein clearance. CRITICAL CAVEAT: in vitro evidence; human clinical translation not established; do NOT use as substitute for evidence-based COVID treatments.
Mechanism of action
Direct Fibrin Cleavage
Nattokinase is a serine protease that directly cleaves fibrin into smaller fragments — same end result as endogenous plasmin. Distinct from anticoagulant drugs (which work upstream by inhibiting clotting factors).
tPA Activation
Nattokinase enhances production and activity of endogenous tissue plasminogen activator (tPA) — increasing physiological fibrinolytic capacity. Both direct (NK cleaves fibrin) and indirect (NK activates plasmin via tPA) mechanisms.
PAI-1 Inhibition
Nattokinase reduces plasminogen activator inhibitor-1 (PAI-1) — a fibrinolysis inhibitor. Lower PAI-1 = greater fibrinolytic activity. PAI-1 elevation associated with metabolic syndrome and CV risk.
Pleiotropic Cardiovascular Effects
Beyond fibrinolysis: BP reduction (mechanism unclear; possibly via ACE inhibition), modest lipid effects, reduced platelet aggregation. Multi-mechanism CV agent.
Clinical trials
Double-blind RCT of nattokinase (2,000 FU/day) vs placebo in 86 prehypertensive adults for 8 weeks.
86 prehypertensive adults.
Nattokinase reduced systolic BP by ~5.5 mmHg and diastolic BP by ~2.8 mmHg vs placebo. Modest but clinically meaningful effect. Subsequent Jensen 2016 trial confirmed similar magnitude.
RCT of nattokinase + pycnogenol vs placebo for DVT prevention in 200 long-haul flight passengers.
200 high-risk flight passengers.
Nattokinase + pycnogenol group: 0% DVT incidence vs 5% in placebo group; significant edema reduction. Combined product limits attribution to nattokinase alone. Suggestive but not definitive.
About this ingredient
Nattokinase is a SERINE PROTEASE (subtilisin NK) produced by Bacillus subtilis natto fermentation of soybeans — the enzyme responsible for the slimy, stringy texture of traditional Japanese natto food. Distinguished from other proteolytic enzymes by SPECIFIC FIBRIN-DEGRADING activity. Standardized in FIBRINOLYTIC UNITS (FU) — typical clinical dose: 2,000-8,000 FU/day (~100-400 mg standardized extract). DISTINCT FROM ANTICOAGULANTS: anticoagulants (warfarin, DOACs) prevent clot FORMATION by inhibiting clotting factors; nattokinase BREAKS DOWN existing fibrin — different mechanism, different clinical use.
EVIDENCE-BASED USES: (1) Modest BP reduction (Kim 2008, Jensen 2016 — ~5 mmHg systolic); (2) Cardiovascular risk marker improvement (fibrinogen, factor VII/VIII, lipids); (3) DVT prevention adjunct (Cesarone 2003 — small trial, combined product); (4) Post-thrombotic syndrome adjunct (limited evidence); (5) Cardiovascular general support. EMERGING/CONTROVERSIAL: (6) LONG-COVID and post-vaccine spike protein concerns — Tanikawa 2022 IN VITRO evidence only; no human clinical trials; do NOT substitute for evidence-based COVID care.
CRITICAL CAUTIONS: (1) BLEEDING RISK — fibrinolytic activity carries bleeding risk; (2) ANTICOAGULANT/ANTIPLATELET COMBINATION — additive bleeding risk; warfarin INR monitoring essential; consult prescriber before combining; (3) PRE-SURGERY — discontinue 1-2 weeks before any surgery; (4) ACTIVE BLEEDING, GI ULCERS, INTRACRANIAL HEMORRHAGE history — AVOID; (5) PREGNANCY/LACTATION — insufficient safety data; AVOID; (6) RECENT STROKE — type-dependent; consult neurologist; (7) SOYBEAN ALLERGY — theoretical cross-reactivity (residual soy protein in standardized products typically very low); (8) ENTERIC COATING — improves stability through gastric acid; some products use enteric coating; (9) STORAGE — heat and acid stability issues; product quality varies; choose reputable brands with FU standardization; (10) DOSE — 2,000 FU is most-studied clinical dose; higher doses (4,000-8,000 FU) used for cardiovascular indications; (11) The 'natural blood thinner' marketing is somewhat misleading — nattokinase is fibrinolytic (clot-busting) rather than anticoagulant; (12) For ESTABLISHED CVD, evidence-based pharmacotherapy (ACEi/ARB, beta-blockers, antiplatelets, statins) remains foundational; nattokinase adjunctive at most.